Immunotherapy plus standard treatment shows promise for head and neck cancer
NCT ID NCT02586207
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times
Summary
This early-phase study tested adding the immunotherapy drug pembrolizumab to standard chemoradiation for people with advanced head and neck cancer. 59 participants received the combination to see if it was safe and helped shrink tumors. The goal was to improve cancer control without increasing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanford Health Cancer Center
Sioux Falls, South Dakota, 57104, United States
-
Sanford-Bismarck Medical Center
Bismarck, North Dakota, 58501, United States
-
Sanford-Roger Maris Cancer Center
Fargo, North Dakota, 58122, United States
-
UCSD Moores Cancer Center
La Jolla, California, 92093-0698, United States
Conditions
Explore the condition pages connected to this study.